Integrating the triptans into clinical practice.
The triptans (selective serotonin agonists) are becoming the first-line alternatives in the acute pharmacological treatment of migraine, at least for attacks of moderate-to-severe intensity. Although clinical trials demonstrate significant differences in efficacy between triptan tablets, they often appear similar in efficacy when used in clinical practice, particularly after dose adjustments. Most patients with migraine consider drugs that can be administered orally to be the most user-friendly. However, gastrointestinal absorption may be impaired during migraine attacks because gastric motility is inhibited, and there is a risk that nausea during the attack will culminate in vomiting. Furthermore, in addition to their antimigraine properties, triptans may prolong the gastric emptying time. For this reason the absorption of any triptan taken orally during the migraine attack will be erratic and treatment effects inconsistent. Despite these barriers to good efficacy and high reliability, the tablet is the most commonly used triptan formulation.
Dahlöf
Carl
C
Institute of Clinical Neuroscience, Gothenburg Migraine Clinic, Sociala Huset, Uppgang D, S-41117 Gothenburg, Sweden. carl.dahlof@migraineclinic.se
D003258:Consumer Behavior; D004333:Drug Administration Routes; D004361:Drug Tolerance / Q000502:physiology; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D009325:Nausea / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000493:pharmacokinetics*; D018170:Sumatriptan / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome
D017366:Serotonin Receptor Agonists; D018170:Sumatriptan